# Gorana Capkun

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gorana-capkun/

## Facts

| Field | Value |
| --- | --- |
| Citations | 728 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 14 |
| i10-index | 16 |
| Last Known Institution | Merck KGaA, Darmstadt (Germany) |
| OpenAlex ID | https://openalex.org/A5002442592 |
| ORCID iD | 0000-0001-9566-4456 |
| Works | 45 |

## Researcher papers

- [Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database](https://scholariq.org/papers/mortality-and-comorbidities-in-patients-with-multiple-sclerosis-compared-with-a/)
- [Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis](https://scholariq.org/papers/persistence-with-and-adherence-to-fingolimod-compared-with-other-disease/)
- [A Systematic Review and Meta-Analysis of Prevalence Studies of Sporadic Inclusion Body Myositis](https://scholariq.org/papers/a-systematic-review-and-meta-analysis-of-prevalence-studies-of-sporadic/)
- [Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study](https://scholariq.org/papers/relapse-rates-in-patients-with-multiple-sclerosis-switching-from-interferon-to/)
- [Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension](https://scholariq.org/papers/network-meta-analysis-combining-individual-patient-and-aggregate-data-from-a/)
- [Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis](https://scholariq.org/papers/development-of-a-novel-machine-learning-model-to-predict-presence-of/)
- [Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis](https://scholariq.org/papers/comparative-effectiveness-of-fingolimod-versus-interferons-or-glatiramer-acetate/)
- [Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis](https://scholariq.org/papers/expanding-the-use-of-administrative-claims-databases-in-conducting-clinical-real/)
- [Essentials of good epidemiological practice](https://scholariq.org/papers/essentials-of-good-epidemiological-practice/)
- [Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA](https://scholariq.org/papers/impact-of-the-covid-19-pandemic-on-healthcare-resource-utilization-across/)
- [Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?](https://scholariq.org/papers/can-we-use-existing-guidance-to-support-the-development-of-robust-real-world/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Hydrology and Watershed Management Studies](https://scholariq.org/topics/hydrology-and-watershed-management-studies/)
- [Inflammatory Myopathies and Dermatomyositis](https://scholariq.org/topics/inflammatory-myopathies-and-dermatomyositis/)
- [Hydrology and Drought Analysis](https://scholariq.org/topics/hydrology-and-drought-analysis/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Merck KGaA, Darmstadt (Germany)](https://scholariq.org/institutions/merck-kgaa-darmstadt-germany/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.